Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Moderate/severe case 11% Improvement Relative Risk PASC 14% c19early.org/ex Pływaczewska-Jakubowska et al. Exercise Prophylaxis Favors exercise Favors inactivity
Lifestyle, course of COVID-19, and risk of Long-COVID in non-hospitalized patients
Pływaczewska-Jakubowska et al., Frontiers in Medicine, doi:10.3389/fmed.2022.1036556
24 Oct 2022    Source   PDF   Share   Tweet
Retrospective 1,847 COVID+ patients in Poland, showing no significant difference in moderate/severe cases with physical activity. Hospitalized patients were excluded.
risk of moderate/severe case, 11.0% lower, OR 0.89, p = 0.30, high activity levels 490, low activity levels 1,357, adjusted per study, multivariable, model 3, RR approximated with OR.
risk of PASC, 14.0% lower, OR 0.86, p = 0.24, high activity levels 389, low activity levels 1,128, adjusted per study, multivariable, model 3, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pływaczewska-Jakubowska et al., 24 Oct 2022, retrospective, Poland, peer-reviewed, median age 51.0, 5 authors, study period May 2020 - January 2022.
Contact: joanna.kapusta@umed.lodz.pl, ma.babicki@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperExerciseAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit